Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has received an average recommendation of “Hold” from the eleven ratings firms that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $22.29.
Several brokerages recently issued reports on ADMS. Northland Securities restated a “buy” rating and set a $28.00 target price on shares of Adamas Pharmaceuticals in a research report on Tuesday, March 5th. ValuEngine upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Mizuho restated a “sell” rating and set a $5.00 target price on shares of Adamas Pharmaceuticals in a research report on Wednesday, April 24th. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, February 7th. Finally, BidaskClub upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 25th.
Shares of ADMS traded down $0.23 during mid-day trading on Friday, hitting $5.73. 266,574 shares of the company traded hands, compared to its average volume of 524,465. The company has a quick ratio of 6.86, a current ratio of 7.03 and a debt-to-equity ratio of 2.00. Adamas Pharmaceuticals has a 1 year low of $5.36 and a 1 year high of $32.90. The stock has a market capitalization of $157.76 million, a price-to-earnings ratio of -1.18 and a beta of 1.35.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.05. The company had revenue of $11.67 million during the quarter, compared to analyst estimates of $12.78 million. Adamas Pharmaceuticals had a negative net margin of 291.22% and a negative return on equity of 122.40%. As a group, analysts expect that Adamas Pharmaceuticals will post -3.87 earnings per share for the current year.
In other Adamas Pharmaceuticals news, CEO Gregory T. Went sold 6,319 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $7.99, for a total value of $50,488.81. Following the completion of the transaction, the chief executive officer now directly owns 176,291 shares in the company, valued at $1,408,565.09. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders sold 8,361 shares of company stock valued at $66,816. Company insiders own 24.90% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Arbitrage SA bought a new position in shares of Adamas Pharmaceuticals in the first quarter worth approximately $33,000. PNC Financial Services Group Inc. bought a new position in shares of Adamas Pharmaceuticals in the first quarter worth approximately $43,000. First Mercantile Trust Co. boosted its position in shares of Adamas Pharmaceuticals by 43.2% in the fourth quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 1,740 shares during the period. Advisor Group Inc. boosted its position in shares of Adamas Pharmaceuticals by 252.0% in the fourth quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 4,510 shares during the period. Finally, Jefferies Group LLC bought a new position in shares of Adamas Pharmaceuticals in the first quarter worth approximately $107,000. Institutional investors and hedge funds own 88.03% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Featured Story: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.